Alonso, J.M.; Escobar-Peso, A.; Fernández, I.; Alcázar, A.; Marco-Contelles, J.
Improving the Efficacy of Quinolylnitrones for Ischemic Stroke Therapy, QN4 and QN15 as New Neuroprotective Agents after Oxygen–Glucose Deprivation/Reoxygenation-Induced Neuronal Injury. Pharmaceuticals 2022, 15, 1363.
https://doi.org/10.3390/ph15111363
AMA Style
Alonso JM, Escobar-Peso A, Fernández I, Alcázar A, Marco-Contelles J.
Improving the Efficacy of Quinolylnitrones for Ischemic Stroke Therapy, QN4 and QN15 as New Neuroprotective Agents after Oxygen–Glucose Deprivation/Reoxygenation-Induced Neuronal Injury. Pharmaceuticals. 2022; 15(11):1363.
https://doi.org/10.3390/ph15111363
Chicago/Turabian Style
Alonso, José M., Alejandro Escobar-Peso, Israel Fernández, Alberto Alcázar, and José Marco-Contelles.
2022. "Improving the Efficacy of Quinolylnitrones for Ischemic Stroke Therapy, QN4 and QN15 as New Neuroprotective Agents after Oxygen–Glucose Deprivation/Reoxygenation-Induced Neuronal Injury" Pharmaceuticals 15, no. 11: 1363.
https://doi.org/10.3390/ph15111363
APA Style
Alonso, J. M., Escobar-Peso, A., Fernández, I., Alcázar, A., & Marco-Contelles, J.
(2022). Improving the Efficacy of Quinolylnitrones for Ischemic Stroke Therapy, QN4 and QN15 as New Neuroprotective Agents after Oxygen–Glucose Deprivation/Reoxygenation-Induced Neuronal Injury. Pharmaceuticals, 15(11), 1363.
https://doi.org/10.3390/ph15111363